EMV Capital PLC (AIM: EMVC) — Investment Research Note

Executive summary

EMV Capital is an AIM-listed deep-tech and life-sciences venture capital investment group managing £112.5m of AUM across ~70 portfolio companies, generating fees from corporate finance, fund management and value creation services. Across the period covered (2021–2025), the company has transformed from a turnaround case to a £100m+ AUM platform, with FY25 group revenue +17% to £2.9m, EMVC Core revenue +31% to £3.2m, and a fair-value uplift of c.£10m from £0.9m invested into the Venture Build programme. The single most important valuation point: the shares trade at 51p versus an Adjusted NAV per share of 106p — a ~52% discount — but a material going-concern uncertainty was flagged by auditors and most of the carrying value sits in Level-3 unobservable inputs.

Fair value estimate

Methodology: Sum-of-the-parts / discount-to-NAV (the only defensible approach for a holding company whose value sits in private portfolio stakes).

Building blocks (from 2025 annual report):

• Direct equity investments at FVTOCI/FVTPL: £14.6m (mostly Level-3, valued at last-round prices)
• Subsidiary/associate director valuations (Glycotest £11m, ProAxsis £8m, EMV Capital Partners £3.6m, DName-iT £1.7m): £24.3m, unaudited
• Net debt (loans £2.1m + lease £0.5m – cash £0.5m – securities £0.3m): c.£1.8m
• Adjusted NAV: £29.7m ≈ 106p/share

Conservative central case applies a 30–50% discount to Adjusted NAV, reflecting (i) typical AIM VC-trust discounts, (ii) Level-3 valuation uncertainty (notably Glycotest, a loss-making US clinical-stage subsidiary at £11m and ProAxsis whose revenue collapsed from £0.5m to £0.1m yet still carries £8m), and (iii) going-concern overhang.

• Fair-value range: 55p – 75p per share
• Implied market-cap range: £15m – £21m GBP
• vs current mcap £13.6m → absolute upside ~28% to midpoint (65p)
• View: undervalued, but only mildly once Level-3 risk is properly haircut.

Sector context

ICB classifies the issuer as Health Care, but the underlying business is best peer-grouped with AIM-listed investment companies / VC trusts (Allied Minds, IP Group, Tekcapital, Frontier IP, Mercia Asset Management). Quality is below typical sector peers: smaller scale (IP Group £700m+ market cap; Mercia £100m+), no realised Venture Build exits yet, weaker balance sheet, going-concern flag. Growth and AUM trajectory is in line with peers; leverage profile is comparable but liquidity tighter.

Investment thesis (3 bullets)

• Substantial discount to a growing NAV with multiple value-creation routes: AUM grew 14% to £112.5m and Venture Build delivered £10m fair-value uplift on £0.9m cost (12.4x) 2026-05 FY2025 results. At 51p the shares are at half Adjusted NAV.
• Self-financing core platform: EMVC Core generated £1.5m profit (vs £1.5m loss prior year) on £3.2m revenue — recurring management fees from Martlet Capital plus corporate-finance commissions now cover a significant share of central costs, reducing dilution risk 2026-05 FY2025 results.
• Optionality from portfolio inflection points: AMR Bio (XF-73 Phase-3 ready antimicrobial acquired from Destiny Pharma administration for £475k cash), Wanda Health (US RPM scaling to $5m+ ARR target by end-2026), Sofant (world-first Ka-band MEMS transmit array demonstrated Oct-2025), and Martlet portfolio (Paragraf, Nu Quantum, Xampla) provide multiple catalysts 2025-12 Wanda update; 2025-12 Sofant update; 2026-05 FY2025 results.

Key risks (3 bullets)

• Material going-concern uncertainty disclosed by auditors: cash of £0.5m at YE25, £0.9m further funding may be needed to June 2027, reliant on a £0.5m unsecured loan facility at 11% — any portfolio cash call could deplete reserves quickly 2026-05 FY2025 results.
• Subsidiary valuations vulnerable to write-down: Glycotest (£11m) is loss-making, late-clinical, raising small CLA tranches; ProAxsis (£8m) revenue collapsed to £0.1m on supply-chain disruption and needs a private fundraise 2026-05 FY2025 results.
• No realised exits validating the IPEV directors' valuations: across five years of filings, the only notable cash realisations are a £0.3m Martlet secondary at 2.5x and £0.4m of PDS Biotech share sales. Value-trap risk is real if exit markets stay closed 2026-05 FY2025 results, 2024-09 interims.

Operating leverage

The EMVC Core platform is the leverage point: a fixed cost base of c.£1.7m (FY25 EMVC Core revenue £3.2m less profit £1.5m) supports corporate-finance, fund-management and VCS revenue lines. The 31% Core revenue increase translated into a £3m swing from a £1.5m loss to a £1.5m profit, partly aided by £1.4m non-cash fair-value gains. Stripping those out, incremental contribution margin on recurring fund-management and VCS fees is high (the Martlet management contract delivers "mid-high six figures" annually with minimal incremental cost); corporate-finance commissions (5% of funds raised) are essentially pure margin once the team is in place. A 10–20% beat on AUM/syndicated capital could plausibly add 50%+ to core operating profit, but the absolute scale is tiny (£1.5m profit) so the dollar uplift on any AI-cycle revenue surprise is structurally capped. Carry on £112.5m AUM at 2x return / 15–20% carry could deliver £3–4m one-day, but timing is multi-year. Operating leverage exists but is modest in absolute pound terms 2026-05 FY2025 results.

Value-trap signals

• Material going-concern uncertainty disclosed three years running (2023, 2024, 2025 reports).
• Cash of £0.5m on £13.7m net assets — perennial liquidity stress.
• Loss-making subsidiaries (Glycotest, ProAxsis, CetroMed) consume ~£2.2m/year of consolidated losses, carried at directors' valuations not market-tested for years.
• Heavy reliance on insider/related-party loans (AB Group / Beckman / Melvin Lawson 14.4% shareholder).
• No portfolio exits achieved in five years of disclosures despite repeated forward references.
• Audit qualification on prior-year valuations (2023 accounts) noted in 2024 interims.
• Persistent share-based settlement of director fees and supplier invoices (dilutive in small doses).

Earnings vs. expectations

The filings include no analyst consensus references and management does not give specific numerical guidance — only qualitative outlook. Year-on-year delivery shows AUM grew from £74m (2023) → £98.5m (2024) → £112.5m (2025) with revenue from £1.6m (2022) → £2.5m (2024) → £2.9m (2025). Where management flagged specific portfolio events (Wanda ARR scaling, Sofant commercial launch, Glycotest HCC validation), delivery has slipped repeatedly: Glycotest assay validation has been pushed from H1 2023 → 2024 → 2025 → "ongoing"; ProAxsis 2025 revenue plan was derailed by an OEM supply pause; full exits have been "encouraging pipeline" without crystallisation. Pattern: AUM and revenue growth has met the cumulative trajectory described in 2020's strategy reset, but portfolio-company milestones routinely slip 12+ months.

Conviction: 2 (low)

Anchors: (i) directors' valuations heavily rely on last-round transactions, and many rounds are EMVC-syndicated which creates a self-marking-the-book dynamic; (ii) two of the largest carrying values (Glycotest £11m, ProAxsis £8m) have not been market-tested in years and the underlying businesses are loss-making with worsening commercial momentum; (iii) going concern flag means a near-term dilutive placing or forced asset sale could reset the equity at substantially lower prices. Limiters on caveats: The Adjusted NAV anchor (106p) is at least audited at the parent level for £14m of FVTOCI assets, providing a floor that is unambiguously above the current price, even after aggressive haircuts.